{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Verastem, Inc.
Verastem, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Verastem, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has seen significant stock performance, achieving a 152.55% return over the past year. The stock is currently priced at $9.90, reflecting notable volatility and a recovery trajectory amid mixed technical indicators and market dynamics.
Verastem, Inc. Experiences Evaluation Revision Amid Strong Market Performance and Volatility
Verastem, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly to $9.29. Over the past year, it achieved a remarkable return of 211.74%, significantly outperforming the S&P 500. The company's performance reflects notable volatility and resilience in the market.
Is Verastem, Inc. technically bullish or bearish?
As of October 10, 2025, Verastem, Inc. shows a mildly bullish trend with mixed technical signals, including bullish MACD and moving averages, despite a bearish weekly RSI and OBV, while significantly outperforming the S&P 500 year-to-date and over the past year.
Is Verastem, Inc. technically bullish or bearish?
As of October 10, 2025, Verastem, Inc. shows a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite bearish signals from the RSI and OBV, and has significantly outperformed the S&P 500 year-to-date with a return of 65.76%.
Is Verastem, Inc. technically bullish or bearish?
As of October 10, 2025, Verastem, Inc. shows a mildly bullish technical trend with mixed indicators, having outperformed the S&P 500 over the past year but underperformed over the last five years.
Is Verastem, Inc. technically bullish or bearish?
As of August 25, 2025, Verastem, Inc. shows a bullish technical trend with strong indicators, including a bullish MACD and moving averages, and has significantly outperformed the S&P 500 with a 1-year return of 252.03%.
Is Verastem, Inc. overvalued or undervalued?
As of August 8, 2024, Verastem, Inc. is rated as risky due to negative valuation ratios and performance metrics, indicating it may be overvalued despite a strong 1-year stock return of 252.03%.
Is Verastem, Inc. overvalued or undervalued?
As of August 8, 2024, Verastem, Inc. is rated as "risky" and overvalued, with a Price to Book Value of -10.88 and a P/E ratio of -2.2227, indicating significant financial distress compared to peers and a poor year-to-date stock performance of -10.64%.
Is Verastem, Inc. technically bullish or bearish?
As of June 20, 2025, Verastem, Inc. shows a neutral technical trend with mixed signals, as weekly indicators are mildly bearish while monthly indicators are mildly bullish, resulting in overall uncertainty despite a significant short-term decline of 44.40% against a 1-year gain of 46.20%.
Who are in the management team of Verastem, Inc.?
As of March 2022, the management team of Verastem, Inc. includes CEO Brian Stuglik and Lead Independent Director Dr. Michael Kauffman, along with Independent Directors Timothy Barberich, Gina Consylman, Alison Lawton, and Eric Rowinsky.
What does Verastem, Inc. do?
Verastem, Inc. is a biopharmaceutical company focused on developing cancer treatments, classified as a micro-cap with a market cap of approximately $291.78 million and a recent net profit of -$52 million. The company operates in the Pharmaceuticals & Biotechnology industry.
How big is Verastem, Inc.?
As of Jun 18, Verastem, Inc. has a market capitalization of 291.78 million and reported net sales of 10.00 million with a net profit of -148.88 million over the latest four quarters. Shareholder's funds are at -28.89 million, and total assets amount to 101.54 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
